Latest Antidepressant Stories
SAN DIEGO, April 22, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.
New funding will accelerate clinical development of rapid-acting treatment for psychiatric disorders BOSTON, April 21, 2015 /PRNewswire/ --
What every pregnant woman should know about the effect of drugs on herself and her baby during the course of her pregnancy.
Researchers from The Children's Hospital of Philadelphia's PolicyLab Say Prescribing Practices Need to Include Thoughtful Risk/Benefit Consideration PHILADELPHIA, April 6, 2015 /PRNewswire-USNewswire/
SAN DIEGO, March 30, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Tom Cannell has joined as Chief Commercial Officer.
- Treatment for Major Depressive Disorder (MDD) in Adults- DUBLIN, March 16, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the U.S.
GIA announces the release of a comprehensive global report on the CNS Therapeutics.
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of
- Contrave® net sales total $6.5 million in first 10 weeks of launch SAN DIEGO, Feb. 25, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.